Beta Bionics stock opens 29% higher in Nasdaq debut

Published 30/01/2025, 18:30
© Reuters.

Thursday marked the Nasdaq Global Market debut of Beta Bionics, Inc. as its initial public offering (IPO) opened for trading at $22 per share. The medical device company, recognized for its advancement in diabetes care technology, priced its IPO at $17.00 per share, offering 12,000,000 shares of common stock.

Under the ticker symbol "BBNX," Beta Bionics shares commenced trading on January 30, 2025. The company anticipates gross proceeds of approximately $204.0 million from the offering, excluding underwriting discounts, commissions, and other offering expenses. Furthermore, the underwriters possess a 30-day option to buy up to an additional 1,800,000 shares at the IPO price, subject to the same deductions, with 475,000 shares potentially sold by Beta Bionics and 1,325,000 by certain selling stockholders as detailed in the prospectus.

The lead bookrunners for this significant offering include BofA Securities, Piper Sandler, and Leerink Partners, with Stifel serving as a bookrunner and Lake Street Capital Markets as the co-manager.

Beta Bionics operates as a commercial-stage medical device company, focusing on the design, development, and commercialization of innovative healthcare solutions. The company aims to enhance the lives of people with diabetes (PWD) who require insulin by using advanced adaptive closed-loop algorithms. Its flagship product, the iLet Bionic Pancreas, is the first FDA-cleared insulin delivery device that autonomously administers each insulin dose. This breakthrough technology is poised to significantly improve treatment outcomes for a wide range of PWD.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.